What question did this study set out to answer?

The aim is to determine if monitoring ustekinumab levels can guide treatment in Crohn’s disease.

P1018Optimizing Therapy in Challenging Crohn’s Disease: Higher Ustekinumab Levels Improve Biological Activity in a Refractory Cohort

View Full Paper

Ask AI

Bookmark

The aim is to determine if monitoring ustekinumab levels can guide treatment in Crohn’s disease.
Prospective observational study conducted at Virgen Macarena University Hospital.
Patients with Crohn’s disease receiving ustekinumab were included and monitored for 12 months.
Epidemiological variables and disease activity were assessed at two time points, with measurements of UST levels and clinical activity using the Harvey–Bradshaw Index.
Patients who achieved biological response after one year had higher baseline UST levels (6 vs. 2.8 μg/mL).
Clinical remission rates increased from baseline to follow-up with intensified regimens (69.1% vs. 47.3%).
UST levels significantly increased in patients receiving intensified treatment (20 μg/mL for IV administration).

No takes yet. Share an insight, caveat, or question.

Observational study reveals that higher ustekinumab levels improve biological activity in Crohn’s disease, indicating treatment guidance potential.

Antuña et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Observational study reveals that higher ustekinumab levels improve biological activity in Crohn’s disease, indicating treatment guidance potential.